Key Points for Decision Makers {#FPar1}
==============================

One in every 200 adults in the five largest countries in the EU has been diagnosed with chronic urticaria, and 40 % of them are currently using a prescription treatment.The impact on patients' lives goes beyond effects on skin; currently treated patients experience higher levels of health-related impairment in their functioning in work and non-work activities and quality of life, and are more frequent users of healthcare than similar individuals without the condition.Practitioners need to be aware of the treatment options and find something that works for each patient.

Introduction {#Sec1}
============

Chronic spontaneous urticaria (CSU) is defined as the "spontaneous appearance of wheals, angioedema or both ≥6 weeks due to known and unknown causes" \[[@CR1]\]. CSU often has no discernable external cause and is associated with an underlying autoimmune mechanism, which can be confirmed by testing for autoantibodies, in 30--50 % of cases \[[@CR2], [@CR3]\]. CSU is the most common type of chronic urticaria, accounting for approximately two-thirds of all cases \[[@CR4]\]. Only a few studies have examined the prevalence of CSU in European countries, and these estimate the rate at between 0.1 and 0.8 % in samples from Sweden, Spain, and Germany \[[@CR5]--[@CR7]\]. The disease is most common among patients aged 20--40 years, but all age groups can be affected \[[@CR4]\]. Studies also consistently show that women suffer from this disease at almost twice the rate of men \[[@CR6]--[@CR8]\].

The burden of CSU can be considerable. Published data on patients with chronic urticaria, including studies specific to CSU patients as well as studies examining chronic urticaria without differentiating between types, indicate that issues with fatigue, pain, and lack of sleep or insomnia are commonly reported, often due to the constant itching that accompanies their urticaria \[[@CR9]\]. The visible lesions can lead to emotional upset and withdrawal from social activities \[[@CR10], [@CR11]\]. Indeed, CSU can lead to psychological complaints such as anxiety, depression, or irritability \[[@CR9]\], which can result in significant reductions in quality of life among CSU patients \[[@CR12]\]. In addition to physical and emotional outcomes, some data indicate CSU symptoms can carry a high socioeconomic burden through a combination of direct healthcare costs and loss of work productivity \[[@CR7]\].

While there is some literature on the relationship between CSU and economic and quality-of-life outcomes, research in this area remains limited, including few studies conducted among Europeans with the condition. Previous research characterizing the condition has drawn samples primarily from individual clinics or small geographic areas; to the authors' knowledge, no study has been conducted describing the humanistic and economic burden within a general population survey \[[@CR5]--[@CR12]\]. The current study estimates the burden of CSU among adults diagnosed with chronic urticaria in terms of health-related quality of life (HR-QOL), self-reported depression, anxiety, and sleep difficulties, work and activity impairment, and healthcare use, using individuals currently using prescription treatment for chronic urticaria as a proxy for CSU.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The present study is a retrospective, cross-sectional analysis of data taken from the 5EU National Health and Wellness Survey (NHWS), which is a large cross-sectional survey designed to reflect health in the general population of France, Germany, Italy, Spain, and the UK. Potential respondents are identified primarily through participation in opt-in online survey panels, with stratified random sampling within the survey panel to ensure representativeness in terms of age and sex, and off-panel recruitment is used to ensure representation of the elderly population using quotas by age and sex. Previous comparisons have shown NHWS data to be consistent with that of other health surveys meant to represent the general population \[[@CR13], [@CR14]\]. The current project incorporates data from the 5EU surveys conducted in 2010 (*N* = 57,805), 2011 (*N* = 57,512), and 2013 (*N* = 62,000); the 5EU NHWS was not conducted in 2012. Because the survey is cross-sectional, and sampling is conducted without regard to previous participation, some respondents have completed the survey more than once. The most recent responses were used for such respondents. Respondents were required to be aged at least 18 years, able to read and write the primary language of the country in which the study was conducted, and to provide informed consent. The protocol and questionnaire for the NHWS was reviewed and approved by Essex Institutional Review Board (Lebanon, New Jersey, USA).

Measures {#Sec4}
--------

### Chronic Spontaneous Urticaria Proxy {#Sec5}

Items to identify respondents with CSU in particular were not included in the NHWS, but the survey respondents were asked to identify which medical conditions they had ever experienced from a list that included "chronic hives (lasting 6 weeks or more)". The term "hives" was used rather than "urticaria" to ensure the language would be understood by patients rather than health professionals. No description of the condition was provided. Those who indicated experiencing chronic hives were asked to indicate whether their chronic hives were diagnosed by a doctor, and whether they were currently using a prescription to treat their chronic hives. The type of prescription was not collected. Those who indicated current use of a prescription were used as the proxy for individuals with CSU (cases) to ensure both diagnosis of chronic urticaria as well as present disease at the time of the survey.

### Health-Related Quality of Life {#Sec6}

The NHWS assessed HR-QOL using the standard recall form (4 weeks) of the SF-12v2 for 2010 and 2011 and the SF-36v2 for the 2013 responses \[[@CR15], [@CR16]\]. These are both generic (i.e., not disease specific) HR-QOL instruments that allow for comparison across health conditions and can be used to produce the same metrics for functional health status. Mental Component Summary (MCS) scores were used to summarize mental health, and Physical Component Summary (PCS) scores were used to summarize physical health. MCS and PCS scores have a mean of 50 and a standard deviation of 10 for the population. Health utility scores were also calculated using the SF-6D algorithm, which provides a preference-based single index measure for health using UK general population values, with a score of 1 equivalent to full health \[[@CR17]\].

### Self-Report of Depression, Anxiety, and Sleep Problems {#Sec7}

Respondents to the survey were asked to indicate which medical conditions they had experienced in the prior 12 months, one of which was depression. Those who indicated experience of depression were considered to have depression. Respondents to the survey were also asked to indicate whether they have experienced a variety of different types of anxiety in the preceding 12 months, including anxiety, general anxiety disorder, panic disorder, phobia, post-traumatic stress, obsessive compulsive disorder, and social anxiety disorder. If a respondent indicated having experienced one or more of these in the past 12 months, they were considered to have anxiety. Likewise, respondents who indicated they had experienced insomnia or sleep difficulties in the prior 12 months were considered to have sleep difficulties. For all conditions, the name of the condition was presented to the respondent without additional description.

### Work and Activity Impairment {#Sec8}

The Work Productivity and Activity Impairment questionnaire was included in the study to measure health-related work and activity impairment \[[@CR18]\]. Only respondents who reported being employed full-time, part-time, or self-employed provided data for absenteeism (work time missed due to health), presenteeism (level of health-related impairment while at work), and overall work impairment (combined absenteeism and presenteeism). All respondents provided data for activity impairment (health-related impairment to non-work activities). All values are reported as percentages and are based on the 7 days prior to the survey.

### Healthcare Utilization {#Sec9}

Healthcare use was defined by visits to different medical providers during the prior 6 months. These included visits to specific types of traditional healthcare providers (HCPs: physicians, nurses, dentists, etc.), which were summed across types of providers to provide a total. Specific types of providers who would be expected to provide care for CSU or the common psychological comorbidities were also considered individually, including general practitioners (GPs), allergists, dermatologists, psychiatrists, and psychologists. Respondents also provided the number of emergency room visits and hospitalizations. Whether the respondent made at least one visit to various types of alternative HCPs (herbalists, acupuncturists, chiropractors, nutritionists, massage therapists, and homeopaths) was also included in the survey, though the number of such visits was not asked.

### Demographic and Clinical Characteristics {#Sec10}

A series of demographic and clinical characteristics were also included to characterize the sample and serve as covariates in the regression models. Age, sex, country of residence, marital status, level of household income, and employment status were included as demographic measures. General health characteristics included body mass index (BMI) calculated from reported height and weight, cigarette smoking, frequency of alcohol use, and days of exercise in past month. The Charlson comorbidity index (CCI) was also calculated from self-reported physician diagnoses of different conditions to represent the level of comorbidity among respondents \[[@CR19]\]. The greater the total index score, the greater the comorbid burden on the patient.

Analysis {#Sec11}
--------

Point prevalence of CSU among adults in the 5EU was estimated using the three possible definitions available in the NHWS (ever experienced, diagnosed by a physician, and currently using a prescription) by applying Horvitz-Thompson weights to respondents according to country, sex, and age as reported for each country in the international database of the US Census in 2013 \[[@CR20], [@CR21]\].

In order to quantify burden, cases were matched to 5EU NHWS respondents who had not experienced chronic urticaria (controls) in a 1:4 ratio. The matching was random without replacement among those sharing the same country, sex, age (exact), and year of survey. Comparisons between cases and matched controls were conducted using chi-squared tests of categorical variables and *t*-tests for continuous and count variables. Generalized linear models were also conducted to adjust for potential confounders. These models took into account cigarette smoking, BMI category, and CCI score, which differed between cases and controls after matching. Models were selected based on the distribution of the outcomes. As the distribution of HR-QOL metrics was roughly normal, linear models were used for these outcomes. Logistic regression was used for depression, anxiety, and sleep difficulties, as these were binary outcomes. Negative binomial models with a log link function were used for all other outcomes, as the distributions were positively skewed and also were over-dispersed for the Poisson distribution.[1](#Fn1){ref-type="fn"} To ease interpretation of the regression models, regression-estimated means are presented at the mean value of the covariates. Additional detail for the regression results, such as significance tests and coefficients for the covariates, odds ratios, and rate ratios, are presented in the Electronic Supplementary Material (ESM) 1.

Results {#Sec12}
=======

There were 175,923 unique respondents across the 3 years of survey data. The prevalence of chronic urticaria currently treated with a prescription was estimated at 0.23 % of the adult population after weighting, with an additional 0.28 % reporting a physician diagnosis, for a prevalence of 0.51 % for diagnosed chronic urticaria. A further 0.12 % reported having experienced chronic urticaria but not having received a diagnosis, for a total prevalence of 0.63 % when considering both diagnosed and undiagnosed cases. The condition was almost twice as common among women as among men, regardless of definition used (Table [1](#Tab1){ref-type="table"}).Table 1Prevalence of chronic urticaria in the 5EU (France, Germany, Italy, Spain, and UK)Chronic urticariaOverallMaleFemaleEver experienced0.63 (0.59--0.67)0.46 (0.41--0.51)0.79 (0.72--0.85)Ever diagnosed0.51 (0.48--0.55)0.34 (0.30--0.38)0.67 (0.62--0.73)Currently treated0.23 (0.20--0.25)0.18 (0.14--0.21)0.28 (0.24--0.31)Data are presented as % (95 % confidence interval)Currently treated respondents are a subset of ever-diagnosed respondents, which is a subset of those who ever experienced chronic urticaria

Bivariate comparisons between cases (*n* = 369) and matched controls (*n* = 1476) indicated that those currently treated for chronic urticaria (cases) were not significantly different from controls in terms of household income, marital status, level of education, frequency of exercise, or alcohol use (all *p* \> 0.10). Cases were less likely to be employed (51.5 vs. 58.6 %, *p* \< 0.05), had higher mean BMI (26.6 vs. 25.5, *p* \< 0.01), and differed in the distribution of BMI and smoking categories (both *p* \< 0.01), which was due to a higher proportion of cases being obese (23.0 vs. 15.9 %) and currently smoking cigarettes (35.5 vs. 28.2 %) than controls. CCI scores were notably higher among those treated for chronic urticaria than among the controls (1.7 vs. 0.3, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}).Table 2Patient characteristics in respondents currently treated for chronic urticaria and matched controlsCharacteristicControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valueAge, mean (SD)44.4 (15.2)44.4 (15.2)1.000Male512 (34.7)128 (34.7)1.000Country1.000 France356 (24.1)89 (24.1) Germany252 (17.1)63 (17.1) UK276 (18.7)69 (18.7) Italy320 (21.7)80 (21.7) Spain272 (18.4)68 (18.4)Employed865 (58.6)190 (51.5)0.014Household income0.125 Below median734 (49.7)202 (54.7) Above median523 (35.4)125 (33.9) Declined to answer219 (14.8)42 (11.4)Married/living w/partner913 (61.9)224 (60.7)0.684Completed university603 (40.9)140 (37.9)0.307BMI, mean (SD) (*n* = 1433 \[362\])25.53 (5.15)26.64 (6.60)0.003\*Exercise (days in past month)6.37 (8.21)6.11 (7.81)0.572CCI, mean (SD)0.29 (0.77)1.72 (5.02)\<0.001\*BMI categories0.009 Underweight50 (3.4)16 (4.3) Normal707 (47.9)152 (41.2) Overweight442 (29.9)109 (29.5) Obese234 (15.9)85 (23.0) Declined to answer43 (2.9)7 (1.9)Smoking status0.009 Current416 (28.2)131 (35.5) Former460 (31.2)115 (31.2) Never600 (40.7)123 (33.3)Alcohol use0.276 Daily101 (6.8)32 (8.7) Less than daily972 (65.9)248 (67.2) None403 (27.3)89 (24.1)Data are presented as *n* (%) unless otherwise indicated*BMI* body mass index, *CCI* Charlson comorbidity index, *SD* standard deviation\* *p* value adjusted for violation of homogeneity of variance assumption

All health outcomes were considerably worse among cases than among matched control respondents. HR-QOL was significantly worse among those currently treated for chronic urticaria than among those who had never experienced chronic urticaria (Fig. [1](#Fig1){ref-type="fig"}a), including mean MCS scores (39.6 vs. 45.5), PCS scores (43.4 vs. 50.2), and SF-6D health utility scores (0.62 vs. 0.71; all *p* \< 0.001). Substantial decrements in HR-QOL outcomes remained among those currently treated for chronic urticaria after adjusting for BMI category, CCI, and smoking, with the adjusted mean scores for cases approximately 5 points lower on both MCS (40.2 vs. 45.4, *p* \< 0.001) and PCS (44.6 vs. 49.9) scores (*p* \< 0.001). Health utility scores were 0.08 points lower after adjustment (0.63 vs. 0.71, *p* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Health-related quality of life among those currently treated for chronic urticaria relative to controls. **a** and **b** present matched comparisons before and after regression adjustment, respectively. Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, body mass index category, and Charlson comorbidity index score.*Error bars* indicate standard error of the mean. All comparisons *p* \< 0.001. *MCS* Mental Component Summary, *PCS* Physical Component Summary

There was also an association between current treatment for chronic urticaria and psychological complaints (Table [3](#Tab3){ref-type="table"}). Self-reported depression was approximately twice as prevalent among cases than among controls (32.8 vs. 14.6 %, *p* \< 0.001). Anxiety was experienced by approximately half of cases, again approximately double the rate among controls (50.9 vs. 22.6 %, *p* \< 0.001), and sleep difficulties were also more common in this group than among controls (58.0 vs. 32.7 %, *p* \< 0.001). The difference in prevalence of these complaints after adjustment for confounders, was similar to the unadjusted figures. The estimated probability of depression was 27.5 vs. 14.7 % for cases and controls, respectively, and the prevalence of anxiety was 47.0 % for cases and 23.3 % for controls (both *p* \< 0.001). The adjusted prevalence of sleep difficulties was also higher among cases than controls (54 vs. 34 %, *p* \< 0.001; Table [3](#Tab3){ref-type="table"}).Table 3Depression, anxiety, and sleep difficulties among respondents currently treated for chronic urticaria and matched controlsMatched comparisonsRegression estimatesControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valueControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valueDepression216 (14.6)121 (32.8)\<0.00114.7 (12.9--16.7)27.5 (23.0--32.5)\<0.001Anxiety333 (22.6)188 (50.9)\<0.00123.3 (21.1--25.6)47.0 (41.7--52.4)\<0.001Sleep difficulties483 (32.7)214 (58.0)\<0.00134.2 (31.7--36.8)54.3 (48.9--59.6)\<0.001Data are presented as *n* (%) or % (95 % confidence interval)Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, BMI category, and CCI score*BMI* body mass index, *CCI* Charlson comorbidity index

Impairment in work and activities is summarized in Table [4](#Tab4){ref-type="table"}. Average levels of absenteeism (13.4 vs. 5.6 %, *p* \< 0.001), presenteeism (33.5 vs. 16.6 %, *p* \< 0.0001), and overall work impairment (39.7 vs. 20.1 %, *p* \< 0.001) among employed cases were almost double those reported by employed matched respondents who had never experienced chronic urticaria. Impairment in non-work activities was also nearly doubled among cases relative to controls (45.5 vs. 25.1 %, *p* \< 0.001). Regression adjustment did little to alter the pattern of results, though the difference in absenteeism was no longer significant (11.9 vs. 5.3 %, *p* = 0.058). Adjusted comparisons for presenteeism (30.5 vs. 16.9 %), overall work impairment (36.6 vs. 20.3 %), and impairment in non-work activities (42.2 vs. 25.5 %) all indicated greater impairment among cases than controls (all *p* \< 0.01).Table 4Impairment in work productivity and non-work activities in respondents currently treated for chronic urticaria and matched controlsMatched comparisonsRegression estimatesControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valueControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valueWork impairment Absenteeism5.6 (18.6)13.4 (26.5)\<0.0015.3 (3.8--7.4)11.9 (5.6--25.3)0.058 Presenteeism16.6 (22.8)33.5 (29.9)\<0.001\*16.9 (14.5--19.6)30.5 (22.0--42.3)0.001 Overall20.1 (27.5)39.7 (33.8)\<0.00120.3 (17.5--23.5)36.6 (26.7--50.2)0.001Activity impairment25.1 (28.1)45.5 (30.8)\<0.001\*25.5 (23.3--27.8)42.2 (35.2--50.5)\<0.001Data are presented as mean % (standard deviation) or mean % (95 % confidence interval)Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, BMI category, and CCI score*BMI* body mass index, *CCI* Charlson comorbidity index, *SD* standard deviation\* *p* value adjusted for violation of homogeneity of variance assumption

Higher levels of healthcare use among cases were also reported by proxy CSU cases (Table [5](#Tab5){ref-type="table"}). Those currently treated for chronic urticaria had approximately six more total HCP visits on average during the 6-month recall period (11.5 vs. 4.8, *p* \< 0.001). Analysis of visits to specific healthcare providers revealed that cases made more visits to dermatologists, allergists, psychiatrists, and psychologists (all *p* \< 0.05). Cases also had notably more emergency visits (1.1 vs. 0.3, *p* \< 0.001) and hospitalizations (0.7 vs. 0.2, *p* \< 0.001) than controls. The pattern of more visits among cases than controls was also seen in the regression results (Table [5](#Tab5){ref-type="table"}). The number of physician visits was approximately twice as high for those currently treated for chronic urticaria relative to controls (9.1 vs. 4.9, *p* \< 0.001). The pattern was fairly consistent across types of providers, including GPs, allergists, dermatologists, and psychiatrists (all *p* \< 0.05), though psychotherapist visits were not significantly different after adjustment (*p* = 0.11). The disparity between cases and controls in ER visits and hospitalizations was smaller after adjustment, but still significant (both *p* \< 0.01).Table 5Number of all-cause healthcare visits during the prior 6 months among respondents currently treated for chronic urticaria and matched controlsType of providerMatched comparisonsRegression estimatesControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valueControl (*N* = 1476)Currently treated for chronic urticaria (*N* = 369)*p* valuePhysician4.82 (6.77)11.47 (18.81)\<0.0014.87 (4.61--5.15)9.06 (8.15--10.09)\<0.001 GP1.87 (2.54)3.73 (5.05)\<0.0011.88 (1.76--2.00)3.52 (3.13--3.96)\<0.001 Allergist0.04 (0.33)0.34 (0.89)\<0.0010.04 (0.03--0.05)0.30 (0.21--0.41)\<0.001 Dermatologist0.11 (0.57)0.56 (1.31)\<0.001\*0.11 (0.09--0.13)0.50 (0.38--0.66)\<0.001 Psychotherapist0.17 (1.39)0.42 (2.13)0.033\*0.11 (0.07--0.17)0.24 (0.10--0.56)0.107 Psychiatrist0.16 (1.49)0.41 (1.72)0.010\*0.14 (0.09--0.20)0.39 (0.18--0.85)0.023ER0.30 (2.00)1.12 (3.35)\<0.0010.28 (0.24--0.33)0.75 (0.57--0.99)\<0.001Hospital0.18 (1.34)0.66 (2.45)\<0.001\*0.16 (0.13--0.20)0.33 (0.22--0.49)0.002Data are presented as mean (standard deviation) or mean (95 % confidence interval)Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, BMI category, and CCI score*BMI* body mass index, *CCI* Charlson comorbidity index, *ER* emergency room, *GP* general practitioner, *RR* rate ratio\**p* value adjusted for violation of homogeneity of variance assumption

Discussion {#Sec13}
==========

The current study suggests that individuals in Europe currently treated for chronic urticaria have substantially worse outcomes than those without chronic urticaria across a variety of domains. This was true both in the comparisons matching for country, age, sex, and year of survey, as well as in regressions adjusting for BMI, smoking, and comorbidities within the matched samples. Differences in HR-QOL exceeded commonly accepted 3-point minimally important differences for MCS and PCS scores; likewise, the 0.08-point decrement in SF-6D far exceeded the 0.03 threshold used for that measure \[[@CR16], [@CR22], [@CR23]\]. Depression, anxiety, and sleep difficulties were also associated with current treatment for chronic urticaria. Health-related impairments in work and non-work activities and healthcare resource use were likewise greater among those with chronic urticaria than among controls.

It is important to consider that the cases in the current study reported current use of a prescription for chronic urticaria rather than CSU per se; the NHWS questionnaires in 2010--2013 did not include any items to differentiate between the types of chronic urticaria. Therefore, the burden quantified here may differ somewhat from that experienced by patients with confirmed diagnoses of CSU. However, as CSU is the most common type of chronic urticaria \[[@CR5]\], many of the individuals with chronic urticaria in this cohort most likely have CSU, suggesting that this limitation is relatively minor. Though currently treated patients may be expected to have higher burden, which leads them to seek treatment, exploratory analyses comparing individuals who have either experienced chronic urticaria or been diagnosed with chronic urticaria also indicate substantial burden and are not limited to the proxy definition of the group reported upon here (ESM 2).

The findings should be considered in light of the limitations of the methodology. The survey is subject to potential biases arising from self-report, such as recall biases, but these biases would be expected to influence responses equally across analysis groups. Although the NHWS is representative of the included countries' adult populations in terms of age and sex, the panel-based recruitment may introduce potential bias for variables that are not incorporated in the sampling strata, such as education. Because both cases and controls were drawn from the same panel, this limitation would also be expected to have little impact on the estimated burden of the condition, though it could have affected the proportion of respondents with chronic urticaria. Likewise, because no description was provided for "chronic hives," some respondents experiencing the condition but unfamiliar with the term may not have been identified in the survey, which may have affected the prevalence estimate for undiagnosed patients. The SF-36v2, used in the NHWS to assess HR-QOL, is a generic instrument that allows measurement of health status in any disease as well as in individuals free of disease. While this allows the health status of these patients to be compared with that of individuals without urticaria or other dermatological conditions, a more specific HR-QOL instrument would provide additional information and potentially a fuller description of the burden of the condition. As indicated earlier, all measures were self-report, which provides the patient perspective though is also potentially subject to bias. Measures also included different recall periods, ranging from 1 week for work and activity impairment to 1 year for anxiety, depression, and sleep difficulties. Healthcare use, which used a 6-month recall period, and psychological complaints, which were recalled over the prior 12 months, may not have coincided with treatment for chronic urticaria for some of the patients. Finally, though measured confounders were either used as matching variables or adjusted for in the regressions, there may have been unmeasured confounders that may account for some portion of the differences in health outcomes between cases and controls (e.g., family history of mental illness), and the cross-sectional design of the study does allow us to differentiate between the causes and consequences of chronic urticaria.

Conclusions {#Sec14}
===========

Despite the above limitations, the results of the current study using the proxy definition of chronic urticaria currently treated with a prescription suggest that CSU imposes a substantial burden on patient well-being and ability to be productive at work and in activities outside of work and is associated with more healthcare use. Depression, anxiety, and sleep difficulties were also notably more common among those currently treated for chronic urticaria. Research incorporating respondents with a confirmed diagnosis of CSU is needed to confirm these findings.
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A series of generalized linear mixed models accounting for the matched structure of the data was also conducted, and resulted in similar conclusions; these results are available from the corresponding author. Because of the similarity in findings and an issue with non-convergence for a few outcomes, only the results of the generalized linear models are presented here.
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